The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index, and 1 are not checked yet.
Direct effect of GLP-1 infusion on endogenous glucose production in humans
Open accessAbstract
Aims/hypothesis Glucagon-like peptide-1 (GLP-1) lowers glucose levels by potentiating glucose-induced insulin secretion and inhibiting glucagon release. The question of whether GLP-1 exerts direct effects on the liver, independently of the hormonal changes, is controversial. We tested whether an exogenous GLP-1 infusion, designed to achieve physiological postprandial levels, directly affects endogenous glucose production (EGP) under conditions mimicking the fasting state in diabetes.Methods In 14 healthy volunteers, we applied the pancreatic clamp technique, whereby plasma insulin and glucagon levels are clamped using somatostatin and hormone replacement. The clamp was applied in paired, 4 h experiments, during which saline (control) or GLP-1(7-37)amide (0.4 pmol min⁻¹ kg⁻¹) was infused.Results During the control study, plasma insulin and glucagon were maintained at basal levels and plasma C-peptide was suppressed, such that plasma glucose rose to a plateau of ~10.5 mmol/l and tracer-determined EGP increased by ~60%. During GLP-1 infusion at matched plasma glucose levels, the rise of EGP from baseline was fully prevented. Lipolysis (as indexed by NEFA concentrations and tracer-determined glycerol rate of appearance) and substrate utilisation (by indirect calorimetry) were similar between control and GLP-1 infusion.Conclusions/interpretation GLP-1 inhibits EGP under conditions where plasma insulin and glucagon are not allowed to change and glucose concentrations are matched, indicating either a direct effect on hepatocytes or neurally mediated inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, infusion of native GLP-1 showed acute effects on glucose metabolism by reducing hepatic glucose production [167,168].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [168]
In the citing paper
“Native GLP-1 did not change free fatty acid (FFA) concentrations or glycerol rate of appearance [168].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [168]
In the citing paper
“Several studies have shown an improvement in hepatic glucose and lipid metabolism after GLP-1 injection [167,168] or GLP-1RA treatment [24,102,169,170,171] either in humans and animal studies.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [168]
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 1×
“The classical physiological actions of glucagon-like peptide-1 (GLP-1) include potentiation of glucose-induced insulin secretion, suppression of glucagon release, inhibition of gastric emptying and enhancement of satiety [1].”
BackgroundThe theoretical bases of indirect calorimetry: A review
Ferrannini, E. (1988) · Metabolism · doi:10.1016/0026-0495(88)90110-2 · Cited by 1,580 · cited 1×
“Substrate oxidation rates were calculated from gas exchange measurements as described [23].”
MethodSelf-citationMeasurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“After starting SRIF infusion, the total glucose and glycerol Ra were calculated using Steele’s equation, as previously described [22].”
MethodGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 1×
“GLP-1 receptors were originally not found in human liver [2].”
BackgroundSvegliati‐Baroni, G., Saccomanno, S., Rychlicki, C., Agostinelli, L., De Minicis, S., Candelaresi, C., Faraci, G., Pacetti, D., Vivarelli, M., Nicolini, D., et al. (2011) · Liver International · doi:10.1111/j.1478-3231.2011.02462.x · Cited by 405
Self-citationØrskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318 · cited 1×
“GLP-1 receptor mRNA has also been described in neurons in the hepatic portal region [7].”
BackgroundKnauf, C. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25764 · Cited by 308 · cited 1×
“Finally, intracerebroventricular GLP-1 administration in mice [18] and peripheral GLP-1 infusions in man [19] increased sympathetic activity.”
BackgroundVagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1
Nakabayashi, H., Nishizawa, M., Nakagawa, A., Takeda, R., & Niijima, A. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.5.e808 · Cited by 204
Cited by
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
“2 hr pancreatic clamp where plasma insulin levels were maintained at concentrations that do not suppress EGP ( 25 pM) (Seghieri et al., 2013), demonstrating that GLP-1 can inhibit hepatic glucose production independent of changes in insulin and glucagon.”
BackgroundIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
“In addition, GLP-1 appears to reduce hepatic glucose output even independent of changes in plasma glucagon.(28) Since the liver does not appear to be equipped with GLP-1 receptors, this has to be mediated indirectly, for example, through the autonomic nervous system.”
BackgroundSelf-citationLipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
“presumably through binding to hepatic GLP-1 receptors and/or mediated by the central/peripheral nervous system [115, 119-122].”
BackgroundNonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases
Samuel, V. T., & Shulman, G. I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.08.002 · Cited by 745
“GLP1 analogs may also act to decrease hepatic glucose production (Seghieri et al., 2013) and possibly decrease hepatic DNL (Armstrong et al., 2016).”
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Metadata
- Authors
- Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E.
- Affiliations
- University of Pisa (IT)
- Istituto di Fisiologia Clinica (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Diabeteszentrum Bad Lauterberg (DE)
- Corresponding author
- Ferrannini, E.
- ORCID
- Venue
- Diabetologia
- Published
- 2012-10-12
- Volume
- 56
- Issue
- 1
- Pages
- 156-161
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W1978334327
- Cited by
- 143
- References
- 30
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 13 · 2023: 7 · 2022: 8 · 2021: 13 · 2020: 8 · 2019: 13 · 2018: 8 · 2017: 11 · 2016: 15 · 2015: 18 · 2014: 11 · 2013: 10
- FWCI
- 10.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon-like peptide-1, endogenous glucose production, hepatic glucose production, glucagon, fasting state, diabetes mellitus, lipolysis, substrate utilization, hepatocytes
- MeSH terms
- Adult, Blood Glucose, Calorimetry, Indirect, Fatty Acids, Nonesterified, Female, Gluconeogenesis, Glucose, Glycerol, Humans, Hypoglycemic Agents, Infusions, Intravenous, Lipolysis, Liver, Male, Peptide Fragments, Sympathomimetics, Glucose Clamp Technique, Up-Regulation, Cross-Over Studies, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Direct effect of GLP-1 infusion on endogenous glucose production in humans. https://app.cochat.ai/papers/10.1007/s00125-012-2738-3
- The paper
- Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E. (2013). Direct effect of GLP-1 infusion on endogenous glucose production in humans. Diabetologia. https://doi.org/10.1007/s00125-012-2738-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.